Scarica l'app Stockscreener
31.65
2.25%
-0.73
Dopo l'orario di chiusura:
31.78
0.13
+0.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$32.38
Aprire:
$32.3
Volume 24 ore:
3.03M
Relative Volume:
0.82
Capitalizzazione di mercato:
$3.58B
Reddito:
-
Utile/perdita netta:
$-99.15M
Rapporto P/E:
-34.03
EPS:
-0.93
Flusso di cassa netto:
$-74.25M
1 W Prestazione:
-10.03%
1M Prestazione:
-16.67%
6M Prestazione:
+4.84%
1 anno Prestazione:
-22.04%
Intervallo 1D:
$31.59
$32.30
Intervallo di 1 settimana:
$31.56
$36.17
Portata 52W:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Confronta VKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
31.65 | 3.66B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-29 | Iniziato | Canaccord Genuity | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics: InvestingPro’s overvalued call proved right amid volatility By Investing.com - Investing.com Nigeria
Can Viking Therapeutics Inc. stock maintain growth trajectory2025 Top Gainers & Safe Capital Allocation Plans - ulpravda.ru
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Finviz
Brokers suggest investing in Viking Therapeutics (VKTX): Read this before placing a bet - MSN
How Viking Therapeutics Inc. stock performs during Fed tightening cyclesPortfolio Performance Summary & Free Daily Entry Point Trade Alerts - ulpravda.ru
Will Viking Therapeutics Inc. stock outperform growth indexes2025 Fundamental Recap & Low Drawdown Momentum Ideas - ulpravda.ru
Viking Therapeutics completes enrollment in trial of VK2735 - TipRanks
Viking Therapeutics (VKTX) Completes Enrollment for Key Metaboli - GuruFocus
Viking Therapeutics completes enrollment in obesity drug maintenance study By Investing.com - Investing.com Australia
Viking Therapeutics completes enrollment in obesity drug maintenance study - Investing.com
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity - PR Newswire
Viking Therapeutics Charts Commercial Course with Key Appointment and Upcoming Investor Presentation - AD HOC NEWS
Viking Therapeutics Faces Headwinds Amid Commercial Push and Insider Sales - AD HOC NEWS
Will Viking Therapeutics’ New CCO Reframe VKTX’s Obesity Strategy Amid Intensifying GLP-1 Competition? - simplywall.st
Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms - Stocktwits
Viking Therapeutics: A Tale of Strategic Hiring and Insider Sales - AD HOC NEWS
Viking Therapeutics Hires Neil Aubuchon as Chief Commercial Officer - Contract Pharma
Viking Therapeutics appoints Neil Aubuchon as chief commercial officer By Investing.com - Investing.com Nigeria
Viking Therapeutics appoints Neil Aubuchon as chief commercial officer - Investing.com India
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer - PR Newswire
Why Viking Therapeutics Stock Crashed Today - AOL.com
Viking Therapeutics (VKTX) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Viking Therapeutics Faces Scrutiny Amid Insider Sales and Key Industry Event - AD HOC NEWS
Here's What $100 Invested in Viking Therapeutics a Decade Ago Would Amount to Now - Bitget
Examining the Latest Short Interest in Viking Therapeutics Inc - Bitget
Looking Into Viking Therapeutics Inc's Recent Short Interest - Benzinga
Insider Sales and Market Competition Weigh on Viking Therapeutics Shares - AD HOC NEWS
Insider Sell Alert: Matthew Foehr Sells 16,000 Shares of Viking Therapeutics Inc (VKTX) - GuruFocus
Viking Therapeutics Insider Sold Shares Worth $7,692,121, According to a Recent SEC Filing - MarketScreener
Viking Therapeutics Insider Sold Shares Worth $1,896,969, According to a Recent SEC Filing - MarketScreener
Leadership Stock Sales Cast Shadow Over Viking Therapeutics’ Prospects - AD HOC NEWS
What drives Viking Therapeutics Inc 1VT stock pricePrice Action Analysis & Low Risk Wealth Building - earlytimes.in
Viking Therapeutics stock suffers worst day in over 4 months as top execs dump shares — Novo’s $149 Wegovy move looms - MSN
Insider Selling: Viking Therapeutics (NASDAQ:VKTX) CEO Sells 233,409 Shares of Stock - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) CFO Sells $1,897,046.90 in Stock - MarketBeat
Marianna Mancini Sells 57,661 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock - MarketBeat
Viking Therapeutics CEO Lian sells $7.69m in shares By Investing.com - Investing.com Nigeria
Viking therapeutics COO Mancini sells $1.9 million in stock By Investing.com - Investing.com Nigeria
Viking Therapeutics CEO Lian sells $7.69m in shares - Investing.com
Viking therapeutics COO Mancini sells $1.9 million in stock - Investing.com
Viking Therapeutics director Foehr sells $561,694 in shares - Investing.com
Viking therapeutics CFO Zante sells $1.89m in shares By Investing.com - Investing.com UK
Viking Therapeutics director Foehr sells $561,694 in shares By Investing.com - Investing.com UK
A Look At Viking Therapeutics (VKTX) Valuation As Long Term Gains Contrast Recent Losses - simplywall.st
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Viking Therapeutics (NASDAQ:VKTX) Trading Down 6.1%What's Next? - MarketBeat
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing - TechStock²
$VKTX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today - AOL.com
Viking Therapeutics 2026: How Brian Lian Built a $4B Metabolic Fortress - CEO Today
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):